Previous 10 | Next 10 |
2023-08-30 12:58:05 ET BioLineRx Ltd. (BLRX) Q2 2023 Earnings Conference Call August 30, 2023 7:30 PM ET Company Participants John Lacey - Head of Investor Relations and Corporate Communications Phil Serlin - Chief Executive Officer Mali Zeevi - Chief Financial O...
2023-08-30 07:02:33 ET BioLineRx press release ( NASDAQ: BLRX ): Q2 GAAP EPS of -$0.02. As of June 30, 2023, the Company held cash, cash equivalents, and short-term bank deposits of $32.8 million and anticipates this will be sufficient to fund operations, as currently plan...
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates PR Newswire - On Track for September 9, 2023 PDUFA Target Action Date on NDA for Motixafortide in Stem Cell Mobilization (SCM) for Autologous Transplantation in Multiple Myel...
2023-08-22 09:27:19 ET Fulcrum Therapeutics ( FULC ) +36% as FDA lifts clinical hold on sickle-cell disease candidate . ProMIS Neurosciences ( PMN ) +30% on $20.4M private placement . Fabrinet ( FN ) +24% on Q4 earnings release . Hallmark Fi...
BioLineRx to Report Second Quarter 2023 Results on August 30, 2023 PR Newswire - Management to Hold Conference Call at 10:00 a.m. EDT - TEL AVIV, Israel , Aug. 22, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial stag...
2023-08-07 14:34:09 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the safest sectors on the market is biotech. After all, we can’t stop people from aging — at least not yet. We have millions of people retiring and demanding better care. T...
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide PR Newswire TEL AVIV, Israel , Jul...
2023-07-10 19:36:22 ET Summary A PDUFA date of September 9, 2023 has been established for review of Motixafortide for Autologous Transplantation in Multiple Myeloma. Results from a phase 2 Columbia University investigator study, using Motixafortide in combination with LIBTAYO + SO...
2023-06-29 14:00:35 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Now is a great time to accumulate top undervalued biotech stocks . For one, the sector is recession-proof. That’s because we can’t stop people from aging, or from seeking ...
2023-05-25 18:21:14 ET If you’re like many retail traders in the stock market today, penny stocks are a popular prospect. This article looks at some of the most active penny stocks today with late-breaking momentum. They could also be on the radar of traders before next week. But...
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) PR Newswire - Investigator-initiated study in...
Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting PR Newswire New analysis of biopsy samples demonstrate...